Back
Monopar Therapeutics Stock Price Chart

Pulling an Uber in the $500 Billion Smartphone Industry
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
72
MNPR
Monopar Therapeutics
Last Price:
$46.34
Seasonality Move:
-10.68%
7 Day Trial
ALL ACCESS PASS
$
7

BOXABL Announces New $20,000 House
Disclosure: *This is a paid advertisement for Boxabl's Regulation A offering. Please read the offering circular here. This is a message from Boxabl-
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and MNPR is experiencing slight selling pressure.
Monopar Therapeutics Price Chart Indicators
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 44.31 | Buy |
20-day SMA: | 36.03 | Buy |
50-day SMA: | 28.53 | Buy |
200-day SMA: | 11.37 | Buy |
8-day EMA: | 44.18 | Buy |
20-day EMA: | 38.04 | Buy |
50-day EMA: | 29.95 | Buy |
200-day EMA: | 15.55 | Buy |
Monopar Therapeutics Technical Analysis Indicators
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | 5.91 | Buy |
Relative Strength Index (14 RSI): | 67.54 | Buy |
Chaikin Money Flow: | -4578 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (24.48 - 42.44) | Buy |
Bollinger Bands (100): | (7.67 - 31.27) | Buy |
Monopar Therapeutics Technical Analysis
Jan 24 | Jan 27 | Jan 28 | Jan 29 | Jan 30 | Jan 31 | Feb 3 | Feb 4 | Feb 5 | Feb 6 | |
---|---|---|---|---|---|---|---|---|---|---|
Jan | Feb | |||||||||
24 | 27 | 28 | 29 | 30 | 31 | 03 | 04 | 05 | 06 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
Technical Analysis for Monopar Therapeutics Stock
Is Monopar Therapeutics Stock a Buy?
-
Monopar Therapeutics share price is 47.11 while MNPR 8-day simple moving average is 44.31, which is a Buy signal.
-
The stock price of MNPR is 47.11 while Monopar Therapeutics 20-day SMA is 36.03, which makes it a Buy.
-
Monopar Therapeutics 50-day simple moving average is 28.53 while MNPR share price is 47.11, making it a Buy technically.
-
MNPR stock price is 47.11 and Monopar Therapeutics 200-day simple moving average is 11.37, creating a Buy signal.
MNPR Technical Analysis vs Fundamental Analysis
Buy
72
Monopar Therapeutics (MNPR)
is a Buy
Is Monopar Therapeutics a Buy or a Sell?
-
Monopar Therapeutics stock is rated a BuyThe current Monopar Therapeutics [MNPR] share price is $47.11. The Score for MNPR is 72, which is 44% above its historic median score of 50, and infers lower risk than normal.
Monopar Therapeutics Stock Info
Market Cap:
248.6M
Price in USD:
47.11
Share Volume:
81K
Monopar Therapeutics 52-Week Range
52-Week High:
51.48
52-Week Low:
1.60
Buy
72
Monopar Therapeutics (MNPR)
is a Buy
Monopar Therapeutics Share Price Forecast
-
What is the Monopar Therapeutics stock price today?The Monopar Therapeutics stock price is 47.11 USD today.
-
Will MNPR stock go up or go down?Monopar Therapeutics> share price is forecast to RISE/FALL based on technical indicators
-
Is Monopar Therapeutics overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Monopar Therapeutics is not overvalued.
Is Monopar Therapeutics Stock a Buy?
-
Monopar Therapeutics share price is 47.11 while MNPR 8-day exponential moving average is 44.18, which is a Buy signal.
-
The stock price of MNPR is 47.11 while Monopar Therapeutics 20-day EMA is 38.04, which makes it a Buy.
-
Monopar Therapeutics 50-day exponential moving average is 29.95 while MNPR share price is 47.11, making it a Buy technically.
-
MNPR stock price is 47.11 and Monopar Therapeutics 200-day simple moving average is 15.55, creating a Buy signal.
Fundamental Analysis of Monopar Therapeutics
Is Monopar Therapeutics a good investment?
-
Analysts estimate an earnings decrease this quarter of $0.50 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.70 per share, and an increase next year of $2.24 per share.
Technical Analysis of Monopar Therapeutics
Should I short Monopar Therapeutics stock?
-
MNPR Moving Average Covergence Divergence (MACD) indicator is 5.91, suggesting Monopar Therapeutics is a Buy
-
Monopar Therapeutics Relative Strength Index (RSI) is 67.54, which suggest Monopar Therapeutics is overbought
-
The Bollinger Bands (25) for Monopar Therapeutics is (24.48 - 42.44), which suggest Monopar Therapeutics is a Buy
-
The Bollinger Bands (100) for Monopar Therapeutics is (7.67 - 31.27), which suggest Monopar Therapeutics is a Buy
* Monopar Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.